DelistingJul 31, 2026, 04:24 PM
PDS Biotechnology Receives Nasdaq Delisting Warning
AI Summary
PDS Biotechnology Corp received a deficiency letter from the Nasdaq Listing Qualifications Department on July 30, 2026, for failing to meet the minimum $1.00 per share bid price requirement for continued listing. The company's common stock has traded below this threshold for the past 30 consecutive business days. PDS Biotechnology has been granted a 180-calendar-day compliance period, until January 26, 2027, to regain compliance. The company intends to monitor its stock price and may consider options such as a reverse stock split to address the deficiency.
Key Highlights
- Received Nasdaq deficiency letter on July 30, 2026, for minimum bid price non-compliance.
- Company's common stock traded below the $1.00 per share minimum for 30 consecutive business days.
- Granted a 180-calendar-day compliance period until January 26, 2027.
- Must achieve a closing bid price of at least $1.00 for 10 consecutive business days to regain compliance.
- May be eligible for a second 180-day compliance period if certain conditions are met.
- Failure to regain compliance could lead to delisting of common stock.
- Company intends to monitor stock price and may consider a reverse stock split.
Price Impact
More from PDSB